DT&CRO CO., Ltd.
Financials
Valuation Metrics
DT&CRO CO., Ltd.'s Market Cap is ₩233B. At end of 2025 it was ₩331B. Ranked #2226 of 2,436 in KR market (top 91%), #1455 of 1,649 on KOSDAQ (top 88%), #223 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 95%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 23.29B KRW | KR#2,226/2,436 Sec#223/234 |
| Revenue | 47.77B KRW | KR#1,806/2,436 Sec#125/234 |
| Net Income | -12.28B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 93.97B KRW | KR#1,793/2,436 Sec#146/234 |
| Net Assets | 11.31B KRW | KR#2,354/2,436 Sec#225/234 |
| Employees | 333 | KR#721/2,436 Sec#63/234 |
| Value | ||
| P/B | 2.06x | KR#1,956/2,436 Sec#145/234 |
| P/S | 0.49x | KR#911/2,436 Sec#38/234 |
| FCF Yield | -53.20% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -108.57% | KR#2,352/2,436 Sec#221/234 |
| ROA | -13.07% | KR#2,146/2,436 Sec#168/234 |
| Op. Margin | -12.22% | KR#2,028/2,436 Sec#140/234 |
| Revenue Growth | 0.20% | KR#1,425/2,436 Sec#136/234 |
| Earnings Growth | -128.65% | KR#1,425/2,436 Sec#93/234 |
| Financial Health | ||
| Debt Ratio | 830.68% | KR#2,340/2,436 Sec#228/234 |
| Total Debt | 49.48B KRW | KR#992/2,436 Sec#68/234 |
| FCF | -12.39B KRW | KR#1,775/2,436 Sec#157/234 |
| Cash | 2.88B KRW | KR#2,167/2,436 Sec#206/234 |
| Current Ratio | 0.66x | KR#2,159/2,436 Sec#206/234 |
| Performance | ||
| 1Y Return | -45.85% | KR#1,983/2,436 Sec#181/234 |
| 1M Return | -0.76% | KR#965/2,436 Sec#89/234 |
| From 52W High | -55.72% | KR#1,488/2,436 Sec#127/234 |
| 1Y MDD | -63.98% | KR#1,640/2,436 Sec#135/234 |
| Trading | ||
| Volume | 44,510 shares | KR#1,410/2,436 Sec#140/234 |
| Foreign Own. | 3.78% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -961 KRW | KR—/2,436 Sec—/234 |
| BPS | 885 KRW | KR#2,309/2,436 Sec#210/234 |
Company Info
Established in 2017 as a CRO providing non-clinical and clinical trial services across various fields, DT&CRO listed on KOSDAQ in 2022. The company conducts non-clinical tests like efficacy, pharmacokinetic, and GLP toxicology studies, as well as bioequivalence and clinical trials, and signed an FDA IND consulting MOU with a US research company in 2024. DT&CRO offers one-stop services from non-clinical to clinical and regulatory approval, emerging as a CRO industry leader through initiatives like AI-powered smart clinical trial platform development. DT&CRO is headquartered in Yongin-si, Gyeonggi-do.